ArticleBiochemistry and biophysics reports2025
Cytoplasmic physicochemical factors drive malignant transformation by adapting bioenergetic settings.
Article in Biochemistry and biophysics reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
While significant insights have been gained by a study of cancer genetics, the roles of the cytoplasm in regulating chemical processes during the transformation to malignancy are often less appreciated. The cytoplasm functions as a two-phase system consisting of an elastic solid phase (the cytomatrix) and a viscous liquid phase (the cytosol). This finding has led to the development of a tumor progression model based on a two-phase system that connects genetic alterations with the physicochemical processes necessary for sustaining and facilitating malignant growth. Here, we show that the energy required for tumor growth is, in part, required for the cytomatrix activity, which accelerates chemical reactions. The ability to regulate cytomatrix motor proteins provides a mechanism to control whether a genetic mutation is able to induce the energy needed for cancer to develop and offers innovative strategies for cancer treatment.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.